Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics reported after the close of the market on Tuesday that its fourth quarter revenues rose nearly 32 percent year over year.

For the three-month period ended Dec. 31, 2018 Interpace's revenues rose to $5.8 million from $4.4 million in the same period the year before, matching the analysts' average estimate.

Interpace reported a Q4 net loss of $4.0 million, or $.14 per share, versus a year-ago loss of $5 million, or $.19 per share. The firm fell short of the analysts' average estimate of a loss of $0.08 loss per share. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.